As European markets navigate a landscape marked by geopolitical tensions and economic uncertainties, the pan-European STOXX Europe 600 Index recently experienced a decline, reflecting broader market sentiment. In such an environment, identifying promising small-cap stocks requires careful consideration of factors like resilience to market volatility and potential for growth in traditionally defensive sectors.

As the pan-European STOXX Europe 600 Index edges just shy of a record high amid positive earnings sentiment, the focus on small-cap stocks remains crucial for investors seeking growth opportunities in a market characterized by cautious optimism and mixed economic signals. In this environment, identifying promising stocks often involves looking for companies with strong fundamentals and innovative strategies that can navigate both current challenges and future uncertainties.

As the pan-European STOXX Europe 600 Index edges closer to record highs amid positive sentiment about future earnings and economic prospects, investors are increasingly looking toward dividend stocks as a source of steady income in a potentially volatile market. In this context, selecting dividend stocks with robust fundamentals and attractive yields can be an effective strategy for those seeking to balance growth with income stability.

If you’re wondering what to do with Mota-Engil SGPS stock, you’re definitely not alone. With shares up an outstanding 131.0% over the past year and an incredible 425.1% gain over the last three years, investors are right to question if the growth story still has room to run. Just in the past week, the stock surged another 13.0%. Part of this can be traced back to a wave of positive market sentiment in the infrastructure and construction sectors, fueled by hefty contract wins across Southern...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

As the pan-European STOXX Europe 600 Index rose by 1.40% amid optimism over potential U.S. rate cuts, European markets have shown resilience, with key indices like Italy's FTSE MIB and the UK's FTSE 100 reaching new highs. In this context of renewed investor confidence and expanding business activity in the eurozone, identifying promising small-cap stocks can be particularly rewarding for those looking to uncover hidden opportunities in Europe's dynamic market landscape.